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Background: Although much research effort has been devoted to elucidating lung cancer, the molecular mechanism
of tumorigenesis still remains unclear. A major challenge to improve the understanding of lung cancer is the difficulty
of identifying reproducible differentially expressed genes across independent studies, due to their low consistency. To
enhance the reproducibility of the findings, an integrated analysis was performed to identify regulatory SNPs.
Thirty-two pairs of tumor and adjacent normal lung tissue specimens were analyzed using Affymetrix U133plus2.0,
Affymetrix SNP 6.0, and Illumina Infinium Methylation microarrays. Copy number variations (CNVs) and methylation
alterations were analyzed and paired t-tests were used to identify differentially expressed genes.
Results: A total of 505 differentially expressed genes were identified, and their dysregulated patterns moderately
correlated with CNVs and methylation alterations based on the hierarchical clustering analysis. Subsequently, three
statistical approaches were performed to explore regulatory SNPs, which revealed that the genotypes of 551 and 66
SNPs were associated with CNV and changes in methylation, respectively. Among them, downstream transcriptional
dysregulation was observed in 9 SNPs for CNVs and 4 SNPs for methylation alterations.
Conclusions: In summary, these identified SNPs concurrently showed the same direction of gene expression changes
with genetic modifications, suggesting their pivotal roles in the genome for non-smoking women with lung
adenocarcinoma.
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Lung cancer has become an important cause of cancer-
related death in the United States, Europe, and world-
wide [1-3]. Although countless research efforts have
been devoted to understanding the etiology of lung can-
cer, the tumorigenesis process still remains unclear. An
important reason to this is the low reproducibility of the
identified differentially expressed genes across independent
lung cancer cohorts. Consequently, even if many prognos-
tic biomarkers have been identified for predicting survival
outcomes for lung cancer patients [4-6]; their application
is usually limited due to the low reproducibility [7,8]. Vari-
ous confounding factors, including heterogeneous sample* Correspondence: chuangey@ntu.edu.tw
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unless otherwise stated.characteristics, different experimental procedures, and
multiple statistical algorithms, may lead to this inconsist-
ency. Since changes at DNA-level are more stable than
that at RNA-level, one possible strategy to improve the
reproducibility is to perform integrated analyses of gene
expression and genome modifications, such as copy
number variations (CNVs) and methylation alterations.
It is well-known that DNA copy number is a causative
factor in driving downstream gene expression changes,
especially in cancer tissues. A previous study has dem-
onstrated that approximately 12% of gene expression
changes can be explained by the concordant CNVs in
breast cancer [9]. In addition, a genome-wide approach
has revealed many recurrent CNVs in lung adenocarcin-
oma [10], and an integrated analysis has reported that
several functionally relevant gene sets were successfully
utilized as prognostic biomarkers for at least three inde-
pendent cohorts [11]. Therefore, with the advancement
in high-resolution karyotyping technologies, such asis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
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are able to investigate genomic landscapes of CNVs en
masse at a lower cost. A comprehensive analysis of con-
current CNVs and gene expression patterns may help to
provide better understanding and identify important
dysregulated genes for lung cancer.
DNA methylation is a common modification mechan-
ism in the regulation of normal physiological function,
and gene expression levels may be affected through al-
tered methylation profiles [12]. Recently, a growing body
of evidence has indicated that changes in DNA methyla-
tion play an important role in tumor initiation and pro-
gression [12-14], perhaps by reactivating oncogenes that
are normally silenced. Conversely, locus-specific hyper-
methylation usually occurs in tumor suppressors and
thus leads to their loss of function. For example, methy-
lation of CDKN2A, a major player in cell cycle regula-
tion, was suggested as a potential biomarker of lung
cancer due to its existence in pre-neoplastic lesions in
smokers, but not non-smokers [15]. In addition to re-
gional methylation alterations, global hypomethylated
patterns in tumor tissue were associated with the pro-
gression of lung cancer [15]. Thus, an integrated analysis
of gene expression and methylation alterations may help
to improve the understanding of gene regulation mecha-
nisms in lung cancer.
High-throughput technologies facilitate the screening
of hotspots for CNVs or methylation alterations in can-
cer studies. However, their use in practice poses a major
problem in that a relatively low frequency of such gen-
omic changes may be reported. For instance, the most
commonly observed amplification in lung adenocarcin-
oma, 14q13.3, was only observed in 12% of samples [10].
To address this issue, several studies have indicated that
some of those genetic modifications were accounted for
by cis-acting regulatory elements [16-18]. Such regulation
mechanisms with allelic asymmetries were widespread in
non-imprinted single nucleotide polymorphisms (SNPs)
and were associated with not only CNVs but also methyla-
tion alterations in many cancer studies [17-19]. Compared
with SNPs identified from genome-wide association
screenings, these regulatory SNPs showing functional rele-
vance have clearer roles in cancer development. In
addition, the differential preferences of tumor cells for
specific SNP alleles have been reported in several cancers
[17-19], suggesting germline alleles are important regula-
tors in driving downstream gene expression. Therefore,
taking this hereditary effect into account may provide a
better understanding of lung cancer etiology.
In this study, we performed an integrated genome-
wide association study with CNVs and methylation alter-
ations in non-smoking lung adenocarcinoma women.
These two genetic modification mechanisms were corre-
lated with downstream gene expression changes, andseveral SNP loci were closely associated with the dysreg-
ulated expression patterns. Differential expression ana-
lyses of the transcription level of these SNP loci
identified nine alleles associated with CNVs and three
alleles associated with methylation alterations. Among
them, those SNPs showing concordant changes (i.e., sim-
ultaneous and in the same direction) in both gene
expression and genetic modification may serve as poten-
tial candidates for further experimental validation in
lung adenocarcinoma.
Methods
Sample collection and microarray experiments
Thirty-two pairs of lung tumor and adjacent normal tissue
specimens from non-smoking female adenocarcinoma pa-
tients were collected from National Taiwan University
Hospital or Taichung Veterans General Hospital. These 32
patients are a subset of the lung cancer patients examined
in our previous studies [6,11] and all of them belong to
adenocarcinoma subtype. The study protocol was con-
ducted in accordance with the Declaration of Helsinki and
was approved by the local ethics committees. All samples
were concurrently analyzed using Affymetrix SNP 6.0, Illu-
mina Infinium Methylation, and Affymetrix U133plus2.0
microarrays. The extraction of DNA and RNA was per-
formed following standard protocols provided by the man-
ufacturers. The mean ± SD age of the patients was 62 ±
10 years, and 78% (25/32) were in stage I or II. These
and other patient characteristics are summarized in
Additional file 1: Table S1 and further details about the
information of sample collection and clinical features is
provided in the previous study [6]. The microarray data
have been submitted to Gene Expression Omnibus with
the accession numbers of GSE19804 [6], GSE33355
[20], and GSE49996.
Microarray data analyses
For gene expression analysis, tumor and adjacent normal
tissues from the same individual were investigated using
an Affymetrix U133plus2.0 microarray. After quality
checks, raw intensity data were imported into Partek
Genomic Suite for analysis. Quantile normalization was
performed to remove systematic bias. Subsequently,
paired t-tests were utilized to identify genes expressed
differentially in tumor and normal tissue.
Genome-wide SNPs were assessed using an Affymetrix
SNP 6.0 array, which contains 906,600 probes in total.
Among all examined SNPs, only those loci with a minor
allele frequency of at least 0.01 and in Hardy-Weinberg
equilibrium (p-value > 0.05) were retained for further
analysis.
In addition to examining the genotyping results, the
intensity data of each SNP probe were imported into
Partek software to perform CNV analysis. Since both
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vidual were investigated, the reference baseline for each
tumor tissue is its own corresponding normal tissue.
Genomic segments were defined if they met the follow-
ing criteria: minimum consecutive genomic markers ≥
100, p-value ≤ 0.001, and signal-to-noise ratio (SNR) ≥
0.3. Among the identified segments, only the regions
with absolute copy number changes of at least 0.3 were
considered copy number variation regions (CNVRs), i.e.,
the copy number of an amplified region was higher than
2.3, and the copy number of a deleted region was lower
than 1.7. The genes located within or overlapping with
these detected CNVRs were annotated by the documen-
tation file provided by Affymetrix.
Whole-genome methylation profiles were analyzed
with the Illumina Infinium Methylation Assay. There
were 27,578 methylation probes, which contained ap-
proximately 20,000 distinct CpG islands and 14,000
unique genes. Similar to the above gene expression and
CNV analyses, paired comparisons were performed to
identify genes with unequal methylation levels. The
threshold of beta value difference between tumor and
normal tissue was defined as 0.25 based on a previous
study [21]. That is, hypermethylated regions were de-
fined if there was a positive difference in beta values
(≥0.25), and hypomethylated regions if there were nega-
tive differences (≤ −0.25).
Associations among copy number, methylation, and gene
expression
To explore the associations among CNVs, methylation,
and gene expression levels, hierarchical clustering was
performed using the Genesis program [22]. The input
data were the gene expression ratios between tumor and
normal tissue of the differentially expressed genes
(Figure 1, middle column). Using the same order of
genes, corresponding CNVs and methylation changes in
those genes were illustrated as heatmaps (Figure 1, left
and right panels, respectively).
Identification of SNP loci associated with copy number
variations
Our procedure for identifying regulatory SNPs associ-
ated with different CNVs in lung tumor and adjacent
normal tissues is outlined in a flowchart (Additional file
1: Figure S1). For each gene in every sample, DNA copy
number status was defined as amplified or deleted, if the
magnitude of its copy number difference between tumor
and normal tissue was larger than 0.3 (i.e., amplified:
CNdif ≥ 0.3; deleted: CNdif ≤ −0.3). For each SNP in a
normal tissue, two coding schemes, considering the
qualitative effects or quantitative effects, were used to
classify patients into different groups. In the qualitative
effect model, a SNP variable of a sample was coded as“0” or “1” for carrying the corresponding allele or not; in
the quantitative effect model, a SNP variable was coded
as “2”, “1,” or “0” to evaluate if the qualitative effect was
additive. To explore the associations between CNVs and
SNP classifications, three statistical approaches were per-
formed under each model. First, for every SNP in all
samples, Fisher’s exact test was applied to a 2×2 or 3×2
contingency table to evaluate whether its specific
groupings were correlated with CNVs (Additional file 1:
Tables S2 and S3). Subsequently, linear regression
models (Additional file 1) were utilized to estimate if
the difference in copy number between tumor and nor-
mal tissue was predicted by the SNP variable. Lastly, a
Kruskal-Wallis test was performed to examine the me-
dian differences in copy number among various SNP
groups, and notably the Kruskal-Wallis test is equiva-
lent to the Wilcoxon rank sum test while the patients
are classified into two groups.
Identification of SNP loci associated with methylation
alterations
In addition to CNVs, the same procedures shown in
Additional file 1: Figure S1 were performed to examine
methylation alterations. For every gene with changes in
methylation, patients were divided into two groups: (a)
the “hypermethylated” group, in which the beta value
differences between tumor and normal tissue were
higher than 0.25, and (b) the “hypomethylated” group, in
which the beta value differences between tumor and
normal tissue were lower than −0.25. Similar to the
above copy number analysis , samples were classified
based on two SNP coding schemes, and the associations
between these specific groups and methylation alter-
ations were evaluated with Fisher’s exact test, linear re-
gression models, and a Kruskal-Wallis test.
Results
Dysregulated patterns among methylation alterations,
copy number variations, and gene expression changes
The whole genome expression profiles of 32 non-
smoking women with lung adenocarcinoma were exam-
ined using Affymetrix U133 plus2.0 expression arrays.
Since both cancerous and adjacent normal tissues from
the same individual were investigated, a paired t-test
was used to identify differentially expressed genes. Five
hundred five genes showed significant changes with p-
values < 10−9, and this criterion was more stringent
than the threshold obtained by Bonferroni correction
(0.05/54675 = 9.14 × 10−7). The expression changes of
the 505 genes are illustrated by a hierarchical clustering
heatmap (Figure 1, middle column). Among them, 369
genes (73%) were down-regulated and 136 genes (27%)
were up-regulated in tumor tissues, a distribution com-
parable to our previous study [6].
Figure 1 Heatmaps of gene expression, copy number variation (CNV), and methylation level of the 505 differentially expressed genes
in tumor tissue. In the gene expression heatmap (middle column), red represents up-regulation and green represents down-regulation. The
gene order was the same in all three panels. For CNV and methylation alteration (left, right columns), one-way hierarchical clustering was first
performed on the β-value difference and subsequently the copy number difference. For CNV (left column), gold indicates amplification and cyan
indicates deletion. For methylation level (right column), blue denotes hypermethylation and yellow denotes hypomethylation.
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these dysregulated genes, CNV analysis was performed
with Affymetrix SNP 6.0 arrays, and whole genome
methylation profiles were assessed with Illumina Infi-
nium Methylation arrays. For CNV analysis, genes weredefined as amplified or deleted if the magnitude of copy
number changes was greater than 0.3; for methylation
analysis, genes were defined as hypermethylated or
hypomethylated if the magnitude of methylation alter-
ations was greater than 0.25. (The detailed procedures of
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described in Materials and Methods.) To visualize these
genetic modifications with their corresponding tran-
scriptional changes, one-way hierarchical clustering was
performed first on differences in methylation level and
subsequently on CNVs (Figure 1, left and right columns).
Although some genes showed CNV and gene expression
changing in opposing directions, about 60% of genes
demonstrated co-varying patterns, especially the amplifi-
cation and deletion clusters (Figure 1, left column). In
addition to CNVs, methylation alterations were associated
with gene expression dysregulations, especially those sim-
ultaneously hypermethylated and down-regulated genes
in the upper half (Figure 1, right column). These results
suggest that CNVs and methylation alterations both
play important roles in modulating downstream tran-
scriptional changes, and concurrent explorations of
them will help to elucidate the regulation mechanisms
in lung adenocarcinoma. To obtain biomarkers for pre-
dicting these genetic modifications in lung tumorigen-
esis, the following analyses focused on regulatory SNPs
with functional relevance to them.
Regulatory SNPs associated with genetic modifications
including copy number variations and methylation
alterations
To identify potential regulators of CNVs and methyla-
tion alterations, whole genome SNPs were investigated
using Affymetrix SNP 6.0 arrays. After excluding those
SNPs not in Hardy-Weinberg equilibrium (p-values <
0.05) and with minor allele frequency lower than 0.01,
511,263 SNPs were collected for further analysis. For
each SNP, two coding schemes, the “qualitative model”
and the “quantitative model,” were used and patients
were divided accordingly into different groups based on
their genotyping results. The qualitative effect model
considered whether the existence of a specific SNP allele
is correlated with genetic modifications, and the quanti-
tative effect model evaluated if there existed additive as-
sociations. To take the above two models into account
simultaneously, we designed a flowchart including three
statistical approaches (Addional file 1: Figure S1).Table 1 Number of significant SNPs in three statistical approa
Kruskal-Wallis test







ap-value threshold was set as 0.01 in three tests.First, Fisher’s exact test was used to explore the rela-
tionships between CNVs and SNP groupings; i.e., for
each SNP in the two models, a 2×2 or 3×2 contingency
table was created and evaluated. As shown in Table 1,
there were 1,048 and 843 SNPs showing significant asso-
ciations with copy number amplifications or deletions,
respectively (p-values < 0.01). Among these SNPs, a lin-
ear regression test was applied to examine whether the
copy number differences were predicted by the coding
variables in each model. The results showed that 551
SNPs successfully predicted the magnitude of CNVs with
p-values of < 0.01, indicating that the correlations be-
tween these SNPs and CNVs were both qualitative and
quantitative. Subsequently, a Kruskal-Wallis test was
used to evaluate the classification performances of the
groupings from those SNPs, which revealed 142 and 95
SNPs with significant copy number differences (p-
values < 0.01). For example, rs3088324 in KDM5B was
associated with amplifications, and rs11966226 in
RNF217 was associated with deletions (Figure 2A-B).
These results indicate that investigation of SNPs and
CNVs concurrently may help to identify dysregulated
hotspots of genetic amplifications/deletions. To explore
whether those CNVs were able to trigger downstream
gene expression changes, a Kruskal-Wallis test was per-
formed on their expression differences according to
SNP groupings. A few SNPs were significantly (p-
values < 0.05, Table 2) associated with corresponding
changes in transcription level, such as KDM5B and
RNF217 (Figure 2C-D), which further demonstrated that
explorations of CNVs based on SNPs may reveal import-
ant hereditary markers during lung tumorigenesis.
In addition to CNVs, the relationships of SNPs and
methylation alterations were examined by the same pro-
cedures described previously. There were 316 and 120
SNPs showing associations with hypermethylation and
hypomethylation, respectively, according to Fisher’s
exact test (Table 1). Among them, linear regression
models indicated that 66 SNPs successfully predicted the
magnitude of methylation alterations. A Kruskal-Wallis
test further excluded 21 SNPs due to insignificant differ-
ences among their specific groupings, which resulted inches including Fisher’s exact test, linear regression, and





Figure 2 Boxplots of two SNPs, rs3088324 and rs11966226, showing significant association with copy number variation. (A-B) Boxplots
were used to demonstrate the difference in copy number between the specific SNPs (AG versus GG for rs3088324 and CC versus CT for rs11966226).
Significance level was determined by a Wilcoxon rank sum test. The Y-axis represents copy number. (A) KDM5B, rs3088324, was correlated with copy
number amplifications. (B) RNF217, rs11966226, was correlated with copy number deletions. (C-D) To evaluate whether CNVs were able to
drive downstream gene expression changes, a Wilcoxon rank sum test was performed on the expression difference between tumor and
normal tissue for each SNP. The two genes, (C) KDM5B and (D) RNF217, both showed significantly differential expression (p-values < 0.05) and
concordance in terms of the direction of change of CNVs and gene expression. The Y-axis denotes relative expression ratios on a log scale.
Dotted lines indicate the unchanging baseline.
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lations, respectively. These results indicate that certain
SNPs might be able to trigger methylation alterations
during lung tumorigenesis. For instance, rs17150656 in
MAGI2 was related to hypermethylation, and rs2123615
in HK2 was related to hypomethylation (Figure 3A-B).
Similar to the analysis of CNVs, gene expression changes
corresponding to these methylation alterations wereexamined by Kruskal-Wallis tests. Four SNPs with rele-
vance to hypermethylation showed significantly differen-
tial expression among the specific groupings, such as
MAGI2 (Figure 3C), but no such SNP was identified
from the pool relevant to hypomethylation (Table 2).
Compared with the results from CNVs, fewer SNPs
associated with methylation alteration were regarded as
significant loci in driving downstream transcription
Table 2 List of SNPs showing differential expression changes based on the SNP groupings
Genetic modification Gene symbol SNP Concordancea
Copy number variations









Hypermethylation MAGI2 rs17150656 +
MYOM2 rs6558659/rs2405327 -
FGF12 rs9881554 -
Hypomethylation — — —
aConcordant (+) or discordant (−) changes in gene expression and genetic modification.
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vestigation, since dysregulated patterns showing con-
cordance in the direction of change of both methylation
alterations and gene expression were observed.
Discussion
In previous studies, several prognostic biomarkers for
lung cancer have been identified based on gene expres-
sion microarrays. However, further clinical applications
of them often resulted in extremely low reproducibility
across independent studies. This may be attributed to
the fact that transcriptional changes related to lung can-
cer tumorigenesis and progression are contributed by
many complicated factors, such as CNVs and changes in
methylation [10,15]. To better elucidate the dysregulated
cancer genome in lung tumorigenesis, we performed an
integrated analysis in non-smoking lung adenocarcin-
oma patients to identify SNP alleles associated with
CNVs and methylation alterations. Gene expression ana-
lysis further demonstrated that several SNP alleles with
genetic modifications correlated with downstream tran-
scriptional changes. By comparing these identified SNP
loci with differentially expressed genes from gene ex-
pression microarrays, we may observe lower false-
positive rates of biomarker identification by limiting
the search to changes that are consistent across three
levels—sequence, epigenomic, and transcriptional—of
the cancer genome in lung adenocarcinoma.
Gene expression analysis identified 505 differentially
expressed genes in 32 lung adenocarcinoma patients,
and most of them were down-regulated in tumor tissue.
Approximately 70% of these genes were identical to
those observed in 60 women with non-small cell lung
cancer in our previous study [6]. Although a higherproportion of significantly down-regulated genes was ob-
served (Figure 1), the number of up-regulated genes in
the whole genome was comparable to that of down-
regulated genes (Additional file 1: Figure S2). This result
is dependent on the threshold selected for significance,
which was p < 10−9 in this study.
Regarding the associations with CNVs and methylation
alterations, it is obvious that more genes showed changes
in copy number than in methylation level (Figure 1). How-
ever, there were many genes (40%) showing discordance
between CNVs and gene expression changes. The reason
for such inconsistent change remains unclear, and it
might imply the existence of other regulatory mecha-
nisms with antagonistic effects at the transcription
level. Therefore, the more genomic changes considered
in the gene expression analysis, the better performance
exhibited by the results.
Compared with CNVs, fewer genes with methylation
alterations were demonstrated (Figure 1), which may be
attributed to the fact that current methylation micro-
array technologies mainly focus on promoter regions
and CpG islands. Recent reports have shown that several
methylated loci were in regulatory regions outside CpG
islands or core promoters [23,24]. For example, methyla-
tion changes occurred in sequences whose nearest pro-
moter or CpG island is 2 kb away in a colon cancer
study [23]. This suggests that experimental methodolo-
gies with higher resolution, such as next-generation
sequencing, are required to improve the detection per-
formance. In our study, the patterns of methylation
alteration correlated moderately with corresponding
gene expression changes, consistent with methylation al-
terations being able to drive downstream gene expres-
sion in cancer cells [23]. We conclude that incorporating
Figure 3 Boxplots of two SNPs, rs17150656 and rs2123615, showing significant association with methylation alterations. (A-B) Boxplots
were used to demonstrate the difference of methylation level between specific SNPs (AA and AG versus GG for rs17150656 and TT and TG versus
GG for rs2123615). Significance level was determined by a Wilcoxon rank sum test. The Y-axis represents methylation differences. (A) MAGI2, rs17150656,
was correlated with hypermethylation. (B) HK2, rs2123615, was correlated with hypomethylation. (C-D) To evaluate whether the methylation
alterations were able to drive downstream gene expression changes, a Wilcoxon rank sum test was performed on the expression difference
between tumor and normal tissue for each SNP. (C) MAGI2 showed significantly differential expression (p-values < 0.05) but (D) HK2 did not.
The Y-axis denotes relative expression ratios on a log scale. Dotted lines indicate the unchanging baseline.
Lu et al. BMC Research Notes  (2015) 8:92 Page 8 of 11such epigenetic modifications into transcriptional ana-
lysis may help to identify genes differentially expressed
in tumorigenesis with lower false discovery rates.
To classify patients into different groups based on the
SNP genotyping results, germline alleles in adjacent nor-
mal tissue were utilized rather than those in tumor tissue.
In general, highly similar results were obtained in both
analyses, since only a few SNPs were different between
tumor and normal tissues. Those SNPs may correspond tosomatic mutations in lung tumorigenesis that preferen-
tially amplify oncogenic alleles in tumor cells. To evaluate
whether there were any SNPs showing significant changes,
Bowker’s test was performed and indicated that no such
varied allele was identified with p-value of < 0.05. Further-
more, another important reason for choosing normal tis-
sue as a reference baseline was that these SNPs represent
hereditary effects and may serve as possible biomarkers
for lung tumorigenesis in advanced applications.
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methylation alterations (Table 1), but only thirteen of
them showed downstream gene expression changes
(Table 2). Among these 13 SNPs, some showed methyla-
tion and transcription changes in the opposite direction
(Figure 4). This low penetration rate from genetic vari-
ation to transcription could result from those SNPs be-
ing identified by random chance, or alternatively, from
other as-yet uncharacterized mechanisms participating
in gene regulation, such as transcription factor andFigure 4 Boxplots of two SNPs, rs41799 and rs6558659, showing disc
(A-B) Boxplots were used to demonstrate the difference in copy number (
versus GG for rs41799 and GG and GT versus TT for rs6558659). Significan
represent copy number (A) or methylation difference (B). (A) NAMPT, rs4
correlated with hypomethylation. (C-D) To evaluate whether the genetic
changes, a Wilcoxon ranksum test was performed on the expression diffe
and (D) MYOM2 both showed significantly differential expression (p-values < 0
DNA modification. The Y-axis denotes relative expression ratios on a log scalemicroRNA activity or histone acetylation. Tumor tis-
sues could use these additional mechanisms to
antagonize the dysregulation effects driven by CNVs
and methylation if they alter the essential genes for
tumor development (i.e., amplifications or hypomethy-
lations on tumor suppressors and deletions or hyper-
methylations on oncogenes). Therefore, those SNPs
without concordant transcriptional changes deserve
further investigation to clarify their roles in lung
adenocarcinoma.ordant changes between DNA modification and gene expression.
A) or methylation level (B) between the specific SNPs (TT and TG
ce level was determined by a Wilcoxon rank sum test. The Y-axes
1799, was correlated with amplification. (B) MYOM2, rs6558659, was
modifications were able to drive downstream gene expression
rence between tumor and normal tissue for each SNP. (C) NAMPT
.05), but in the opposite direction with respect to the corresponding
. Dotted lines indicate the unchanging baseline.
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tions and transcriptional changes (Table 2), some have
been reported in previous studies to serve as important
players in cancer cells [25-29]. For instance, knockdown
of SMYD3 induced apoptosis through G1-phase cell
cycle arrest in breast cancer cell line MDA-MB-231 [26],
and MAGI2 cooperates with PTEN to inhibit the growth
of tumor cells by suppressing the activation of Akt [28].
KDM5B, also known as JARID1B, was required to main-
tain tumorigeneic activity in melanoma cells [29], and
the knockdown of KDM5B may trigger apoptosis and re-
duces proliferation in bladder and lung cancers [25].
Therefore, ongoing efforts are warranted to further elu-
cidate the roles these identified SNPs play in lung
tumorigenesis.
Conclusions
An integrated analysis of gene expression, SNPs, CNV,
and methylation alteration was performed in 32 non-
smoking women with lung adenocarcinoma. Moderate
correlations were demonstrated between genetic modifi-
cations and gene expression levels, indicating that con-
current analysis of DNA and RNA levels may improve
the homogeneity of the findings. The integrated protocol
proposed in this study revealed unidirectional transcrip-
tional changes in 9 SNPs for CNVs and 4 SNPs for
methylation alterations. Further functional studies are
warranted to elucidate the biological roles of these SNP-
gene combinations in lung adenocarcinoma.
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